Background: Breast cancer occurs in both men and women, although it is more prevalent among women. Mammography is generally the diagnostic imaging modality of choice, but it is limited in the detection of breast cancer in young women, aged 18-45 years due to the dense nature of their breast tissue. Aims and Objectives: This review explores whether MRI should replace mammography as the initial screening modality for asymptomatic women, aged 18-45 years at high risk of developing breast cancer. Materials and Methods: A systematic review of the literature was undertaken. A search of Medline, Pubmed central, Cinahl and Google scholar for English language literature from 2004 to 2015 was undertaken. Also a review of reference lists, author searching and review of NICE evidence base for exiting guidelines was done. Included studies were assessed for bias using STARD quality assessment tool and data were extracted systematically using a purposefully designed data extraction form. Result: From the seven included studies, 179 participants of the total population had breast cancer and a total of 199 breast cancer was detected by both modality used. MRI detected a total 148 breast cancers compared to 78 detected by mammography, and 10 interval cancer was reported. Sensitivity estimate from the included studies ranged from 25% to 100% while specifi city ranged from 79% to 99%. MRI detected more breast cancer but had a moderate specifi city compared to mammography as reported in the literature. Conclusion: In the absence of contraindication and accessibility, MRI should be used as the initial screening modality for asymptomatic women aged 18 -45 years, at high risk of developing breast cancer.
INTRODUCTION
Breast cancer in asymptomatic women aged 18 to 45 years who are predisposed to the gene mutation (Breast cancer 1(BRCA1) and Breast cancer 2 (BRCA2)) or with a strong family history of breast cancer are often given less attention. 1 In 2012, out of the 14.1 million new cases of cancer diagnosed in the world, 1.7 million were due to breast cancer in women, which represent an incidence rate of 25% of all cancers in women. 2 It is however noted that breast cancer susceptibility gene (BRCA1 and BRCA2) may be responsible for 5 -10% of all breast cancer cases in the general population. 3 And the carriers of this susceptibility gene, faces a lifetime risk of 60% to 80% of developing the disease. 4, 5 In asymptomatic women aged 18 to 45 years at high risk of developing breast cancer, mutational test is Should MRI replace mammography as the initial screening modality for asymptomatic women aged 18 -45 years at high risk of developing breast cancer? A systematic review usually recommended for them. The test is performed by mutation screening to identify the gene (BRCA1 and BRCA2). The mutational screening processes involve a combination of proteins-truncation test and heteroduplex analysis, supplemented with linkage analysis of BRCA1 and BRCA2 alleles. 6 BRCA1 and BRCA2 mutation accounts for 20% to 25% of hereditary breast cancer 7 and in young asymptomatic women aged 18 to 45 years at high risk, BRCA1 and BRCA2 are held responsible for the development of the breast cancer and often both breasts are affected by the disease. 8 Breast cancer at advanced stage in asymptomatic women aged 18 to 45 years are usually of the aggressive subtype with adverse pathological factors, which may include high grade tumours, lymphovascular invasion, hormone receptor negativity, and HER2 overexpression. 9, 10 These are usually classifi ed as HER2-positive breast cancer (those that test positive to the protein -Human Epidermal growth factor Receptor 2 (HER2)). It becomes imperative to detect this cancer at an early age in these women and also in older women for effective management of the disease. Over the years Mammography has been used in the screening of breast cancer and in the reduction of breast cancer mortality in postmenopausal women by about 20% to 35%. 11 It was reported to have a sensitivity of about 36% -46% and specifi city of 93% -99.8%. [12] [13] [14] [15] [16] But has a known limitation in the detection of breast cancer in younger women aged 18 to 45 years, due to the dense nature of their breast tissues, leading to increased mammographic densities which obscure radiologic features of early breast cancer. 17 More so germ line mutation gene (BRCA1 and BRCA2) which are associated with breast cancer in young high risk women have benign appearance on mammography, especially BRCA1. 17 In this group of women, mammography is reported to have a sensitivity of about 25% and specifi city of 96.8%. 15 However, approximately 6.6% of all breast cancer cases are diagnosed in women younger than 40 years, while 2.4% of these are diagnosed in women less than 35 years and 0.65% in women less than 30 years. 10 The impact of this limitation was reduced by the introduction of adjunct screening modalities such as highfrequency breast Ultrasound, Clinical breast examination (CBE), and Magnetic resonance imaging (MRI). Currently, annual clinical breast examination, Surgery, Radiation therapy and mammography (beginning at age 40), are used in the management of women at high risk of developing breast cancer.
This review is set to explore whether Magnetic Resonance Imaging (MRI) should replace mammography as the initial screening modality for asymptomatic women, aged 18-45 years at high risk of developing breast cancer.
MATERIALS AND METHODS
A search of Medline, PubMed Central (PMC), and Cinahl databases and Google scholar was undertaken supplemented by hand searching of some imaging journals (Synergy and British journal of Radiology; Radiography), review of the National Institute for Health & Care Excellence (NICE) evidence base for existing guidelines. Also review of reference lists, author searching was undertaken. Citations were identifi ed using the Medical Subject Heading terms (MeSH) and key search terms and their alternatives: Breast cancer (Asymptomatic; BRCA1; BRCA2), Magnetic Resonance Imaging (MRI; MR; Nuclear Magnetic Resonance (NMR)); Mammography (Mammo). The search was limited to primary research studies published in English from 2004 to July 2015, in order to take advantage of recent technological advancement in MRI. After the identifi cation of potential relevant research studies, the title, abstracts and when necessary the full text of the yielded search result, were screened to determine whether they met the inclusion/exclusion, which was derived from the primary research question "Should MRI replace mammography as the initial screening modality for asymptomatic women aged 18-45 years at high risk of developing breast cancer?" and are listed in Table 1 . The rule out principle was employed in the selection of included primary research papers and where the reviewer was certain that a paper lack the necessary information, they were rejected. However at each stage where the reviewer was uncertain, whether a paper should be included, the paper was retained. All retained paper was re-examined to make fi nal decision on inclusion/exclusion.
The included papers were assessed for quality using the Standards for Reporting of Diagnostic Accuracy (STARD), 18, 26 by at least 2 authors and data were extracted into Microsoft Excel 27 spread sheet for consistency using a purposefully designed data extraction form. However paper's with uncertainty in quality was resolved through discussion and consensus was reached. The STARD 26 assessment checklist was used to document the paper quality ( Table 2) . Each article were then rated to determine the overall quality, using Good, Fair or Poor rating scale. Four studies had an overall quality rating of 'Good' and three had a 'Fair' overall rating. This implies that a thorough methodology was used and common bias of diagnostic accuracy studies was low. However none of the included studies was ratted poor. A fi nal value of award was given to each paper, where 'High' was given to a study with low risk of bias, 'Average' was given to studies with an unclear risk of bias and 'low' was given to studies with a high risk of bias in the fi nal evaluation ( Table 3 ).
The data extracted was compared and data analysis was done by descriptive synthesis. 24 A Meta-analysis was inappropriate due to the variations in the extracted data, technical parameters, methods of determining diagnostic accuracy and clinical characteristic. Figure 1 shows a flow chart diagram, detailing the review process. The detail of the included studies and quality assessment awarded are summarized in Table 3 . Tables 4 and 5 holds the details of the index test characteristics and extracted outcome measures.
RESULTS

Sensitivity estimates
All the included studies, used biopsy and positive test (Histopathology) as the reference standard. Sensitivity across the included studies ranged from 71% to 100%. In two studies (Leach et al. 14 19 (2007) administered intravenously 0.1 mmol/kg and 20ml. They reported a sensitivity of 77% and 86% respectively, which was lower than that reported by Lehman et al. 22 (2005) and Kuhl et al. 15 (2005) who administered consistently 0.1 mmol/kg bodyweight.
Specificity estimates
Specifi city across the included studies ranged from 79% to 97%. The study by (Leach et al. 14 (2005) ) reported a specifi city of 81% but there was no record of specifi city reported by Hagen et al. 19 (2007) . The study by Weinstein et al. 21 (2009) reported the lowest specifi city at 79% with all other studies reporting a sensitivity of 90% and higher. 
Diagnostic accuracy analysis
A total of 199 cancer was diagnosed, of which 148 was detected by MRI and 78 by Mammography. Among this detected cancers, it was observed that some type of cancers was detected more on one modality than on the other, this is summarise in Table 5 . Three studies reported 10 interval cancer, 12, 13, 19 while four studies did not. 14, 15, 20, 21 Mammography had the lowest sensitivity between 25% to 50% and a high specifi city between 93% and 99%, while MRI had the highest sensitivity between 71% to 100% and a low specifi city of 79% to 97%. The diagnostic yields are summarized in Table 6 . Similarly, a plot of sensitivity and specifi city for each modality is graphically demonstrated on Figure 2 . It was observed that the sensitivity of all the included studies for MRI, showed a slight difference in the sensitivity values, while that for Mammography shows a cluster of similar sensitivity values when plotted against specifi city. From the graph, the area of the circle illustrate the sample size, a larger circle area represents a larger sample size. The results consistently show's that the specifi cities of MRI and mammography are similar but that the sensitivity of mammography is consistently lower than that of MRI.
DISCUSSION
In these review, from the seven included studies, a pool of 4,793 asymptomatic women at high-risk of developing breast cancer were screened, most of whom were BRCA1 and BRCA2 mutation carrier and women with a strong family history of breast cancer. Of which 199 breast cancers was detected in 179 participants. A total of 444 participants were either withdrawn or excluded from the studies.
A high sensitivity of 71% to 100% and a low specifi city of 79% to 97% were reported for MRI, and a low sensitivity of 25% to 50% and a high specifi city of 93% and 99% were also reported for Mammography. MRI was found in all the included studies to be more sensitive in the screening of asymptomatic women (18-45 years) at high-risk of developing breast cancer compare to Mammography. The highest sensitivity in this review for MRI was reported by Lehman et al. 22 with a sensitivity of 100% and the lowest was reported by Weinstein et al. 21 with a sensitivity of 71%. Hagen et al. 19 reported the highest sensitivity for Mammography to be 50% and Lehman et al. 22 reported the lowest with a sensitivity of 25%. The huge difference in the sensitivity between MRI and mammography reported could be as a result of the comparative nature or biological factor of the breast of the screened population (18- the study, since the sensitivity of mammography is inversely related to the density of the breast.
However, comparing the specifi city of the two modalities, mammography was found to have a high specifi city than MRI in fi ve of the included studies with the highest specifi city of 99.9%, 12 and the lowest with 93%, 14 while that reported for MRI was 97% 15 and 79%. 21 From this fi nding, there is only a slight difference in the specifi city between both modality, which may be statistically signifi cant in clinical practice.
However the true negative for MRI compared to Mammography was also slightly lower with a difference of 8 (Table 7) , this slight difference could be attributed to the fact that only two studies 12, 15 actually gave a report for true negative (TN) values.
Similarly, false positive (FP) outcome was found to be higher screening with MRI than with Mammography (Table 7) , which lead to increase number of participant who were sent for biopsy, compared to those sent from Mammography. The biopsy recommendation rate for MRI in three studies report 15, 21, 22 was 25%, 8.5%, 78% and for Mammography, 29%, 2.2%, 59% respectively. Four of the other included studies did not give values for the biopsy recommendation rates for both modalities. This indicate that the biopsy recommendation rate was higher in MRI, exception of the 29% reported by Weinstein et al. 21 for mammography, which was higher than the 25% reported for MRI.
The positive predictive values (PPV) for both of the modality also shows some signifi cant difference, two of the included studies 15, 22 reported higher PPV for MRI (12.9%, 50%) than Mammography (12.5%, 23.7%) respectively. While in two other studies, 12, 14 Mammography had a higher PPV than MRI, (10%, 80% Vs 7.3%, 42%) respectively. There was no report on PPV in the other three studies. 19, 21, 23 A total of 111 Invasive cancer (IC) (56% of total cancer detected) and 40 Ductal carcinoma in situ (DCIS) (20% of total cancer detected) was detected in the course of the screening among the seven studies. It was observed from most of the included studies that Mammography was better in detecting DCIS compared to MRI. The reason for this could be as a result of the presence of micro-calcifi cations that is associated with DCIS, which can easily be detected by mammography. However four of these studies did not specify the actual number of DCIS detected by each of the various modalities as seen in the data extracted on Table 5 . Only three of the studies gave values for the number of DCIS detected. 15, 22, 23 Base on the few available data, the fi nding cannot be a conclusively one, which gives more room for further confi rmation.
Furthermore, the diagnostic yield found for MRI and mammography was reported by three studies 15, 21, 22 In these reports, it was noted that the diagnostic yield of mammography, was higher than that of MRI in two of the studies, 15, 21 where the percentages of the diagnostic yield for mammography was 40% and 2.1% Vs 16% and 1.1% for MRI, respectively. On the other hand, MRI was higher in Lehman et al. 22 report and was reported to be 0.8% vs 0.3% for mammography. There was no report in four of the other studies. 12, 14, 19, 23 Also, due to the rapidly progressive nature of some breast cancer associated with high risk population, some of the studies performed annual primary examination and also a follow up examinations on the study population. Table 5 holds a summary of the given follow up periods of each of the included studies, although no follow up report was given in Lehman et al. 22 and a median follow up period of 0.5 years and 5.3 years was reported by Kuhl et al. 15 and Hagen et al. 19 From the results of the follow ups, it was observed that MRI was still signifi cantly more sensitive compared to mammography in the screening of asymptomatic women at high risk in the review population.
CONCLUSION
The evidence from this review demonstrate that MRI has a high sensitivity, and detected more breast cancer compared to that reported for mammography, in spite of its low specifi city. Base on this evidence and in line with NICE guideline 25 , we suggests in our conclusion that, MRI should be used as the initial screening modality for asymptomatic women aged 18 -45 years at high risk of developing breast cancer in the absence of any contraindication and accessibility.
LIMITATIONS STRENGTH
This systematic review was undertaken as part of a Master of Science award at the University of Bradford. The review was initially done by AG under the supervision of BS. For publication purpose, the review process was repeated with independent evaluation by DM to ensure rigour of systematic review process.
One of the major limitations in this systematic review was observed during the data synthesis process. As a result of insuffi cient reports of some parameters required for a meta-analysis, only a descriptive synthesis was done for the review. Thus the review lacks homogeneity verifi cation using statistical test of meta-analysis which could lead to some limitation in drawing the conclusion of the fi ndings.
Also the review could suffer from publication bias, due to the fact that non-English language studies were excluded.
In the course of the review, it was however noted that some of the studies reviewed did not provide suffi cient reports on some of the data's need to be extracted.
More so, most of the studies had a wide variation in the age range for their study population and some did not confi ne the study within the age range for this review, which could also be a possible source of bias. 
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